Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?
Related Questions
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
What are your top takeaways in Breast Cancer from ASTRO 2024?
How do you treat metastatic adenoid cystic carcinoma of breast primary, ER 3%, PR, HER 2 negative with liver only metastasis?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
How are you requesting testing for HER2-ultralow status, in light of DB-06 trial demonstrating benefit of T-DXd for these patients?
What initial treatment would you offer a patient with metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
What is your recommended treatment sequencing strategy in patients with HER2+ breast cancer and leptomeningeal carcinomatosis?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
What are your top takeaways in Medical Oncology from SABCS 2024?